COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells

被引：0
|
作者：
Naoise C. Synnott
David O’Connell
John Crown
Michael J. Duffy
机构：
[1] University College Dublin,UCD School of Medicine, Conway Institute of Biomolecular and Biomedical Research
[2] University College Dublin,UCD School of Biomolecular & Biomedical Science
[3] St. Vincent’s University Hospital,Department of Medical Oncology
[4] St. Vincent’s University Hospital,UCD Clinical Research Centre
来源：
Breast Cancer Research and Treatment | 2020年 / 179卷
关键词：
p53; TP53; COTI-2; Triple-negative breast cancer; Treatment; APR-246;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：47 / 56
页数：9
相关论文
共 50 条
  • [31] Immunohistochemical status of p53 as prognostic factor in patients with node negative triple-negative breast cancer
    Bae, S. Y.
    Lee, J. E.
    Lee, S. K.
    Nam, S. J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] Deregulated MicroRNAs involved in P53 Signaling Pathway in Breast Cancer with Focus on Triple-negative Breast Cancer
    Naeimzadeh, Yasaman
    Heidari, Zahra
    Razban, Vahid
    Khajeh, Sahar
    CURRENT MOLECULAR PHARMACOLOGY, 2024, 17
  • [33] Knockdown of SPON2 inhibits the growth of triple-negative breast cancer
    Hu, Xueyi
    Su, Caiwu
    Wei, Jian
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [34] α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73
    Tiwary, Richa
    Yu, Weiping
    Sanders, Bob G.
    Kline, Kimberly
    BREAST CANCER RESEARCH, 2011, 13 (01)
  • [35] α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73
    Richa Tiwary
    Weiping Yu
    Bob G Sanders
    Kimberly Kline
    Breast Cancer Research, 13
  • [36] Differences in prognosis by p53 expression after neoadjuvant chemotherapy in triple-negative breast cancer
    Bae, Soo Youn
    Lee, Jeong Hyeon
    Bae, Jeoung Won
    Jung, Seung Pil
    ANNALS OF SURGICAL TREATMENT AND RESEARCH, 2020, 98 (06) : 291 - 298
  • [37] Ki-67, p53, and clinical outcomes of patients with triple-negative breast cancer
    Nishiyama, Yasuyuki
    Nishimura, Reiki
    Osako, Tomofumi
    Okumura, Yasuhiro
    Arima, Nobuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (27)
  • [38] P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients
    Pan, Yunbao
    Yuan, Yufen
    Liu, Guoshi
    Wei, Yongchang
    PLOS ONE, 2017, 12 (02):
  • [39] Targeting triple negative breast cancer: Is p53 the answer?
    Turner, Natalie
    Moretti, Erica
    Siclari, Olimpia
    Migliaccio, Ilenia
    Santarpia, Libero
    D'Incalci, Maurizio
    Piccolo, Stefano
    Veronesi, Andrea
    Zambelli, Alberto
    Del Sal, Gianni
    Di Leo, Angelo
    CANCER TREATMENT REVIEWS, 2013, 39 (05) : 541 - 550
  • [40] Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Prelinical investigation with the anti-p53 drug, APR-246.
    Synnott, Naoise C.
    Murray, Alyson M.
    O'Donovan, Norma
    Crown, John
    Duffy, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345